Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
CAMBRIDGE, MA—Mitchell Micah, the Chief Commercial Officer of Myomo, Inc. (NYSE:MYO), has sold 48,000 shares of the company’s common stock. The transaction, completed on March 14, 2025, was executed at an average price of $5.1576 per share, totaling approximately $247,564. The sale comes as InvestingPro data shows MYO shares have gained over 10% in the past week, though currently trading below their 52-week high of $7.17.
The sales were conducted in open market transactions at prices ranging from $5.055 to $5.25 per share. Following the sale, Micah retains ownership of 140,572 shares in the company. According to InvestingPro analysis, the company currently appears overvalued relative to its Fair Value, with analysts setting price targets ranging from $6.75 to $11.00 per share.
Myomo, Inc., a company specializing in orthopedic, prosthetic, and surgical appliances and supplies, is headquartered in Boston, Massachusetts. The company maintains strong liquidity with a current ratio of 3.22 and holds more cash than debt on its balance sheet. For deeper insights into MYO’s insider trading patterns and comprehensive financial analysis, investors can access the full Pro Research Report on InvestingPro.
In other recent news, Myomo Inc . reported its fourth-quarter 2024 financial results, showcasing a notable year-over-year revenue increase of 154% to $12.1 million, surpassing analyst expectations of $9.9 million. The company also reported a net loss of $0.01 per share, which was better than the forecasted $0.02 loss per share. Myomo’s gross margin improved to 71%, and it achieved its first positive Adjusted EBITDA of $200,000. The company ended the quarter with $25 million in cash and cash equivalents, positioning it well for future operations.
H.C. Wainwright responded to these financial results by raising Myomo’s stock price target to $9.50 from $7.50 and maintained a Buy rating. The analysts highlighted the company’s strong sales performance and operational improvements as factors for the upgrade. Myomo’s revenue guidance for 2025 suggests continued growth, with projections between $50 million and $53 million, indicating a 54% to 66% increase over 2024. This growth is expected to be driven by expansion in Medicare and international markets.
The company is also focusing on strategic market expansion and increased advertising spend to support future growth. Myomo’s efforts in the orthotics and prosthetics (O&P) channel have shown progress, with revenue in this area growing to $600,000 in the fourth quarter. Internationally, Myomo’s business in Germany performed well, contributing over $1 million in profitable revenue. These recent developments reflect Myomo’s ongoing efforts to enhance its market presence and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.